SG11201906301UA - Methods of manufacture of nut flours and formulations for oral immunotherapy - Google Patents
Methods of manufacture of nut flours and formulations for oral immunotherapyInfo
- Publication number
- SG11201906301UA SG11201906301UA SG11201906301UA SG11201906301UA SG11201906301UA SG 11201906301U A SG11201906301U A SG 11201906301UA SG 11201906301U A SG11201906301U A SG 11201906301UA SG 11201906301U A SG11201906301U A SG 11201906301UA SG 11201906301U A SG11201906301U A SG 11201906301UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- formulations
- nut
- methods
- manufacture
- Prior art date
Links
- 235000013312 flour Nutrition 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 238000009169 immunotherapy Methods 0.000 title abstract 3
- 235000014571 nuts Nutrition 0.000 abstract 5
- 239000003814 drug Substances 0.000 abstract 3
- 102220547770 Inducible T-cell costimulator_A23L_mutation Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 235000017060 Arachis glabrata Nutrition 0.000 abstract 1
- 241001553178 Arachis glabrata Species 0.000 abstract 1
- 235000010777 Arachis hypogaea Nutrition 0.000 abstract 1
- 235000018262 Arachis monticola Nutrition 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 235000020232 peanut Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
- A23L25/30—Mashed or comminuted products, e.g. pulp, pastes, meal, powders; Products made therefrom, e.g. blocks, flakes, snacks; Liquid or semi-liquid products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Seeds, Soups, And Other Foods (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 July 2018 (19.07.2018) WIP0 1 PCT omitia °nolo 011101110100111H 0111111 oimIE (10) International Publication Number WO 2018/132733 Al (51) International Patent Classification: A23L 5/20 (2016.01) A23L 7/10 (2016.01) (21) International Application Number: PCT/US2018/013612 (22) International Filing Date: 12 January 2018 (12.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/446,147 13 January 2017 (13.01.2017) US (71) Applicant: AIMMUNE THERAPEUTICS, INC. [US/US]; 8000 Marina Boulevard, Suite 200, Brisbane, CA 94005-1884 (US). (72) Inventors: SIMON, Reyna, Joy; c/o Aimmune Therapeu- tics, Inc., 8000 Marina Boulevard, Suite 200, Brisbane, CA 94005-1884 (US). BIRRINGER, Nicholas, William; c/o Aimmune Therapeutics, Inc., 8000 Marina Boulevard, Suite 200, Brisbane, CA 94005-1884 (US). (74) Agent: WEINER, Ethan, M. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) 11 N 11 00 11 O C (54) Title: METHODS OF MANUFACTURE OF NUT FLOURS AND FORMULATIONS FOR ORAL IMMUNOTHERAPY (57) : The present technology relates generally to methods of manufacture of nut flours and/or formulations, ultra-low fat nut flours and uses for nut flour formulations. In particular, several embodiments are directed to methods of manufacturing ultra-low fat tree nut or peanut flour formulations for oral administration in immunotherapy of subjects affected by allergies.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762446147P | 2017-01-13 | 2017-01-13 | |
| PCT/US2018/013612 WO2018132733A1 (en) | 2017-01-13 | 2018-01-12 | Methods of manufacture of nut flours and formulations for oral immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906301UA true SG11201906301UA (en) | 2019-08-27 |
Family
ID=62838507
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913846XA SG10201913846XA (en) | 2017-01-13 | 2018-01-12 | Methods of manufacture of nut flours and formulations for oral immunotherapy |
| SG11201906301UA SG11201906301UA (en) | 2017-01-13 | 2018-01-12 | Methods of manufacture of nut flours and formulations for oral immunotherapy |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913846XA SG10201913846XA (en) | 2017-01-13 | 2018-01-12 | Methods of manufacture of nut flours and formulations for oral immunotherapy |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20180200361A1 (en) |
| EP (1) | EP3568027A4 (en) |
| JP (2) | JP2020514306A (en) |
| CN (1) | CN110381749A (en) |
| AU (2) | AU2018207167A1 (en) |
| CA (1) | CA3050093A1 (en) |
| IL (1) | IL267882A (en) |
| MX (1) | MX2019008419A (en) |
| SG (2) | SG10201913846XA (en) |
| WO (1) | WO2018132733A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2924349B1 (en) | 2007-12-03 | 2010-01-01 | Dbv Tech | ALLERGEN DISENSIBILITY METHOD |
| US9492535B2 (en) | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
| EP3482771B1 (en) | 2013-03-14 | 2023-01-18 | Société des Produits Nestlé S.A. | Manufacture of peanut formulations for oral desensitization |
| WO2016033094A1 (en) | 2014-08-25 | 2016-03-03 | Aimmune Therapeutics, Inc. | Egg protein formulations and methods of manufacture thereof |
| US11452774B2 (en) | 2015-02-20 | 2022-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| US10166286B2 (en) | 2015-02-20 | 2019-01-01 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| US10149904B2 (en) | 2015-02-20 | 2018-12-11 | The Board Of Trusteees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| SG11202000419QA (en) | 2017-07-18 | 2020-02-27 | Before Brands Inc | Methods for making mixed allergen compositions |
| MX2020004683A (en) | 2017-11-02 | 2020-08-13 | Aimmune Therapeutics Inc | Methods of oral immunotherapy. |
| CN112638413A (en) | 2018-07-27 | 2021-04-09 | 艾慕恩治疗公司 | Oral immunotherapy unit dose dispensing systems and methods |
| EP3914098A1 (en) | 2019-01-23 | 2021-12-01 | Before Brands, Inc. | Methods for making mixed allergen compositions |
| CN113966229A (en) | 2019-05-10 | 2022-01-21 | 爱沐疗法公司 | Method for improving the quality of life of peanut allergic patients |
| US20230330169A1 (en) * | 2019-12-23 | 2023-10-19 | Prota Therapeutics Pty Ltd | Pharmaceutical compositions |
| CN112890199B (en) * | 2021-02-27 | 2022-05-31 | 中国农业科学院油料作物研究所 | Composition for stably and efficiently regulating immunologic function and preparation and application thereof |
| US20240151702A1 (en) * | 2021-03-05 | 2024-05-09 | Societe Des Produits Nestle S.A. | Methods of making and assessing allergenic tree nut compositions |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU641135B2 (en) * | 1990-01-08 | 1993-09-16 | Procter & Gamble Company, The | Improved nut butter and nut solid milling process |
| US20120164306A1 (en) * | 1993-08-03 | 2012-06-28 | Girsh Leonard S | Process for preparing hypoallergenic and reduced fat foods |
| US6197356B1 (en) * | 1993-08-03 | 2001-03-06 | Immunopath Profile, Inc. | Process for preparing hypoallergenic foods |
| US7381434B2 (en) * | 2003-04-08 | 2008-06-03 | Herbalscience Llc | Methods and compositions of Areca catechu |
| BRPI0708505A2 (en) * | 2006-03-03 | 2011-05-31 | Specialty Protein Producers Inc | fat separation processes from soybean materials and compositions produced therefrom |
| JP2012240975A (en) * | 2011-05-20 | 2012-12-10 | Nitto Denko Corp | Pharmaceutical composition and jerry-form preparation |
| WO2013087119A1 (en) * | 2011-12-16 | 2013-06-20 | Hal Allergy Holding B.V. | Pharmaceutical formulations and the use thereof for the treatment of peanut allergy |
| EP3482771B1 (en) * | 2013-03-14 | 2023-01-18 | Société des Produits Nestlé S.A. | Manufacture of peanut formulations for oral desensitization |
| CN103535508A (en) * | 2013-10-22 | 2014-01-29 | 陕西天玉实业有限公司 | \Walnut protein powder and preparation method thereof |
| PL3258962T3 (en) * | 2015-02-20 | 2023-04-24 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| CN106165870B (en) * | 2016-07-08 | 2020-03-31 | 北京市农林科学院 | Walnut defatted whole powder and preparation method and application thereof |
-
2018
- 2018-01-12 SG SG10201913846XA patent/SG10201913846XA/en unknown
- 2018-01-12 CN CN201880016691.0A patent/CN110381749A/en active Pending
- 2018-01-12 SG SG11201906301UA patent/SG11201906301UA/en unknown
- 2018-01-12 AU AU2018207167A patent/AU2018207167A1/en not_active Abandoned
- 2018-01-12 WO PCT/US2018/013612 patent/WO2018132733A1/en unknown
- 2018-01-12 CA CA3050093A patent/CA3050093A1/en active Pending
- 2018-01-12 US US15/870,477 patent/US20180200361A1/en not_active Abandoned
- 2018-01-12 EP EP18739367.3A patent/EP3568027A4/en active Pending
- 2018-01-12 JP JP2019538225A patent/JP2020514306A/en active Pending
- 2018-01-12 MX MX2019008419A patent/MX2019008419A/en unknown
-
2019
- 2019-07-07 IL IL267882A patent/IL267882A/en unknown
-
2022
- 2022-07-25 JP JP2022118106A patent/JP2022136170A/en active Pending
-
2023
- 2023-03-15 US US18/121,826 patent/US20230233672A1/en active Pending
- 2023-04-28 AU AU2023202625A patent/AU2023202625A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3050093A1 (en) | 2018-07-19 |
| US20180200361A1 (en) | 2018-07-19 |
| JP2022136170A (en) | 2022-09-15 |
| CN110381749A (en) | 2019-10-25 |
| SG10201913846XA (en) | 2020-03-30 |
| IL267882A (en) | 2019-09-26 |
| AU2018207167A1 (en) | 2019-07-25 |
| US20230233672A1 (en) | 2023-07-27 |
| JP2020514306A (en) | 2020-05-21 |
| WO2018132733A1 (en) | 2018-07-19 |
| MX2019008419A (en) | 2019-12-02 |
| EP3568027A4 (en) | 2020-11-11 |
| EP3568027A1 (en) | 2019-11-20 |
| AU2023202625A1 (en) | 2023-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906301UA (en) | Methods of manufacture of nut flours and formulations for oral immunotherapy | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201906412SA (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201808314QA (en) | Compositions and methods for the treatment of wounds, disorders, and diseases of the skin | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201908088RA (en) | Antibodies against pd-l1 | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201803983UA (en) | Transformable tagging compositions, methods, and processes incorporating same | |
| SG11201908420WA (en) | Compositions of plinabulin and use thereof | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201804443UA (en) | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201901494UA (en) | Acid-alpha glucosidase variants and uses thereof | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201809100QA (en) | Use of gram negative species to treat atopic dermatitis |